Lawrence Group publications
Selected highlight publications
1. (Co-last) *Choo, N., *Ramm, S., Luu, J., Winter, J. M., Selth, L. A., Dwyer, A. R., Frydenberg, M., Grummet, J., Sandhu, S., Hickey, T. E., Tilley, W. D., Taylor, R. A., Risbridger, G. P., *Lawrence, M. G. and *Simpson, K. J. (2021). "High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids." SLAS Discovery 26(9): 1107-1124
https://doi.org/10.1177/24725552211020668
This was a collaborative study with the Victorian Centre for Functional Genomics.
We reported a 3D assay for drug screening with organoids grown from patient-derived xenografts of prostate cancer. It was highlighted in a white paper from Perkin Elmer.
2. (Co-last) *Risbridger, G. P., *Clark, A. K., *Porter, L. H., Toivanen, R., Bakshi, A., Lister, N. L., Pook, D., Pezaro, C. J., Sandhu, S., Keerthikumar, S., Quezada Urban, R., Papargiris, M., Kraska, J., Madsen, H. B., Wang, H., Richards, M. G., Niranjan, B., O'Dea, S., Teng, L., Wheelahan, W., Li, Z., Choo, N., Ouyang, J. F., Thorne, H., Devereux, L., Hicks, R. J., Sengupta, S., Harewood, L., Iddawala, M., Azad, A. A., Goad, J., Grummet, J., Kourambas, J., Kwan, E. M., Moon, D., Murphy, D. G., Pedersen, J., Clouston, D., Norden, S., Ryan, A., Furic, L., Goode, D. L., Frydenberg, M., *Lawrence, M. G. and *Taylor, R. A. (2021). "The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology." Nature Communications 12(1): 5049.
https://t.co/GcC0osoUiK
This manuscript reports 59 patient-derived xenografts of prostate cancer collected from 30 patients between 2012-2020. It also demonstrates the use of patient-derived models for rapid in vivo screening of combination therapies for prostate cancer. This paper was featured in “Editor’s Highlights in Cancer” for 50 best papers in Nature Communications, an editorial by Charlotte Bevan in Nature Communications “Breaking down walls in prostate cancer with the MURAL collection of patient-derived xenografts”, and a Research Highlight by Tim Thomas in Nature Reviews Urology “The MURAL Prostate Cancer PDX Collection”.
3. (Co-last) Porter, L. H., Bakshi, A., Pook, D., Clark, A., Clouston, D., Kourambas, J., Investigators, M., *Goode, D. L., *Risbridger, G. P., *Taylor, R. A. and *Lawrence, M. G. (2021). "Androgen receptor enhancer amplification in matched patient-derived xenografts of primary and castrate-resistant prostate cancer." Journal Pathology 254(2):121-134.
https://doi.org/10.1002/path.5652
This paper reports matching patient-derived xenografts of castrate-sensitive primary prostate cancer and metastatic castration resistant prostate cancer collected from the same patient. It was featured on the cover of the June 2021 issue and selected as an “Editor’s Choice” article by Editor in Chief with image featured on the journal’s home page.
4. (Co-first) *Lawrence, M. G., *Porter, L. H., Choo, N., Pook, D., Grummet, J. P., Pezaro, C. J., Sandhu, S., Ramm, S., Luu, J., Bakshi, A., Goode, D. L., MURAL, Sanij, E., Pearson, R. B., Hannan, R. D., Simpson, K. J., Taylor, R. A., Risbridger, G. P. and Furic, L. (2021). "CX-5461 sensitises DNA damage repair proficient castrate-resistant prostate cancer to PARP inhibition." Molecular Cancer Therapeutics 20(11): 2140–2150.
https://doi.org/10.1158/1535-7163.MCT-20-0932
This study used patient-derived xenografts and organoids to test a new combination therapy for castration-resistant prostate cancer.
5. (Co-first) *Lawrence, M. G., *Obinata, D., *Sandhu, S., *Selth, L. A., *Wong, S. Q., Porter, L. H., Lister, N., Pook, D., Pezaro, C. J., Goode, D. L., Rebello, R. J., Clark, A. K., Papargiris, M., Van Gramberg, J., Hanson, A. R., Banks, P., Wang, H., Niranjan, B., Keerthikumar, S., Hedwards, S., Huglo, A., Yang, R., Henzler, C., Li, Y., Lopez-Campos, F., Castro, E., Toivanen, R., Azad, A., Bolton, D., Goad, J., Grummet, J., Harewood, L., Kourambas, J., Lawrentschuk, N., Moon, D., Murphy, D. G., Sengupta, S., Snow, R., Thorne, H., Mitchell, C., Pedersen, J., Clouston, D., Norden, S., Ryan, A., Dehm, S. M., Tilley, W. D., Pearson, R. B., Hannan, R. D., Frydenberg, M., Furic, L., Taylor, R. A. and Risbridger, G. P. (2018). "Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy." European Urology 74(5): 562-572.
10.1016/j.eururo.2018.06.020
This manuscript reported a series of patient-derived models established in collaboration with the CASCADE rapid autopsy program. The study was featured in a Platinum Priority Editorial in European Urology by A/Prof Simon Crabb, University of Southhampton. Media coverage included SBS World News and Herald Sun, reaching ~545,000 people.
6. (Co-first) *Pidsley, R., *Lawrence, M. G., Zotenko, E., Niranjan, B., Statham, A., Song, J., Chabanon, R. M., Qu, W., Wang, H., Richards, M., Nair, S. S., Armstrong, N. J., Nim, H. T., Papargiris, M., Balanathan, P., French, H., Peters, T., Norden, S., Ryan, A., Pedersen, J., Kench, J., Daly, R. J., Horvath, L. G., Stricker, P., Frydenberg, M., Taylor, R. A., Stirzaker, C., Risbridger, G. P. and Clark, S. J. (2018). "Enduring epigenetic landmarks define the cancer microenvironment." Genome Research 28(5): 625-638
https://genome.cshlp.org/content/28/5/625.long#
This collaborative study with the Garvan Institute reported the genome-wide methylation landscape of patient-derived cancer-associated fibroblasts. It was featured on the cover of the May 2018 issue.
7. (Co-first) *Lawrence, M. G., *Porter, L. H., Clouston, D., Murphy, D. G., Frydenberg, M., Taylor, R. A. and Risbridger, G. P. (2020). "Knowing what's growing: Why ductal and intraductal prostate cancer matter." Science Translational Medicine12(533).
https://www.science.org/doi/10.1126/scitranslmed.aaz0152
This review makes the case for detailed reporting of prostate cancer pathology. It has been cited by the Advanced Prostate Cancer Consensus Conference.